CDH1 and prostate adenocarcinoma: KM analysis revealed that high CDH1 mRNA expression correlated with improved overall survival in prostate adenocarcinoma patients (hazard ratio (HR): 0.67 (95% CI: 0.58-0.79), P < 0.0001), while comparison of wild-type versus mutated groups showed no survival difference (HR: 0, P = 0.75), with similar risk reduction trends in both groups (Figure 10A).